MedTrace Logo

Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT

NCT01968239 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2018-12-03

No results posted yet for this study

Summary

The aim of the trial is to evaluate the efficacy and safety of intravitreal injections of ranibizumab for the treatment of macular edema due to BRVO if the re-treatment regimen is guided by morphological macular changes detected by OCT compared to re-treatment according to SmPC defined re-treatment criteria (in case of increase of CRT and concomitant decrease of BCVA).

Conditions

  • Branch Retinal Vein Occlusion

Interventions

DRUG

Ranibizumab

comparison of different re-treatment criteria for intravitreal injection of ranibizumab

Sponsors & Collaborators

  • University of Leipzig

    lead OTHER

Principal Investigators

  • Matus Rehak, MD, Ph.D. · Department of Ophthalmology, University of Leipzig, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-06-17
Completion
2016-12-20

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01968239 on ClinicalTrials.gov